InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Allogene Therapeutics, Inc.

ALLO Clue Score24
United States Fiscal year ends December CIK 0001737287 Results filed 5 Nov 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

15
Insider
Date
Role
Action
Shares
Price
Amount
Geoffrey M. Parker
21 Oct 2026
Chief Financial Officer
Sell
36,342
$1.34
$48.70K
Earl Martin Douglas
21 Aug 2026
SVP, General Counsel
Sell
29,697
$2.12
$62.96K
Annie Yoshiyama
21 Apr 2026
SVP, Finance
Sell
9,586
$2.31
$22.14K
Benjamin Machinas Beneski
31 Mar 2026
SVP, Chief Technical Officer
Sell
2,867
$2.50
$7.17K
David D Chang
16 Mar 2026
President and CEO
Sell
47,763
$2.47
$117.97K
Benjamin Machinas Beneski
16 Mar 2026
SVP, Chief Technical Officer
Sell
4,835
$2.47
$11.94K
Benjamin Machinas Beneski
2 Mar 2026
SVP, Chief Technical Officer
Sell
7,132
$2.60
$18.54K
Zachary Roberts
2 Feb 2026
EVP of R&D
Sell
35,700
$1.77
$63.19K
Annie Yoshiyama
2 Feb 2026
SVP, Finance
Sell
4,167
$1.72
$7.17K
Earl Martin Douglas
2 Feb 2026
SVP, General Counsel
Sell
22,900
$1.76
$40.30K
Geoffrey M. Parker
2 Feb 2026
Chief Financial Officer
Sell
24,001
$1.76
$42.24K
David D Chang
2 Feb 2026
President and CEO
Sell
95,269
$1.80
$171.48K
Benjamin Machinas Beneski
2 Feb 2026
SVP, Chief Technical Officer
Sell
7,549
$1.73
$13.06K
Zachary Roberts
21 Jan 2026
EVP of R&D
Sell
26,269
$1.56
$40.98K
Benjamin Machinas Beneski
17 Nov 2025
SVP, Chief Technical Officer
Sell
786
$1.22
$958.92

What was left out

Form 4 filings counted 25
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 15
Transactions with no price 0
Shares from compensation/vesting 95,400
History held since 17 Oct 2018